Observation on the effect of urinary kallidinogenase combined with edaravone in the treatment of acute cerebral infarction
Objective To investigate the clinical effect of urinary kallidinogenase combined with edaravone in the treatment of patients with acute cerebral infarction.Methods A total of 120 patients with acute cerebral infarction admitted to Shandong Province Liaocheng City Chiping District People's Hospital from January 2021 to December 2022 were selected as the research subjects.They were divided into observation group and control group,with 60 cases in each group,using the random number table method.The control group was treated with edaravone,while the observation group was treated with urinary kallidinogenase combined with edaravone.The treatment effect,daily living ability and neurological function scores were compared between two groups.Results The total effective rate of the observation group was 95.00％,which was higher than 78.33％of the control group,and the difference was statistically significant(x2=7.212,P＜0.05).Before treatment,there was no statistically significant difference in ADL scores between the two groups(P＞0.05);after treatment,the ADL scores of the two groups were higher than before treatment,and the observation group was higher than the control group,and the differences were statistically significant(P＜0.05).Before treatment,there was no statistically significant difference in NIHSS scores between the two groups(P＞0.05);after treatment,the NIHSS scores of both groups were lower than before treatment,and the observation group was lower than the control group,and the differences were statistically significant(P＜0.05).Conclusion The application of urinary kallidinogenase combined with edaravone in the treatment of acute cerebral infarction patients could achieve more significant therapeutic effects.It could not only improve the patient's neurological function,but also enhance their daily living ability,which was worthy of clinical promotion and application.
NETL
NSTL
万方数据
